

WHAT IS CLAIMED IS:

- Sub C
1. A method of cloning a pig, comprising:
- (i) inserting a desired differentiated pig cell or cell nucleus into an enucleated pig oocyte, under conditions suitable for the formation of a nuclear transfer (NT) unit;
 - (ii) activating the resultant nuclear transfer unit; and
 - (iii) transferring said cultured NT unit to a host mammal such that the NT unit develops into a fetus.
2. The method according to claim 1, which further comprises developing the fetus to an offspring.
3. The method according to claim 1, wherein a desired DNA is inserted, removed or modified in said differentiated pig cell or cell nucleus, thereby resulting in the production of a genetically altered NT unit.
4. The method according to claim 3, which further comprises developing the fetus to an offspring.
5. The method according to claim 1, which comprises culturing said activated nuclear transfer unit until greater than the 2-cell developmental stage.
- 54

c 6. The method according to claim 1, wherein the differentiated pig cell or ^{differentiated pig} cell nucleus is derived from mesoderm.

c 7. The method according to claim 1, wherein the differentiated pig cell or ^{differentiated pig} cell nucleus is derived from ectoderm.

c 8. The method according to claim 1, wherein the differentiated pig cell or ^{differentiated pig} cell nucleus is derived from endoderm.

c 9. The method according to claim 1, wherein the differentiated pig cell or ^{differentiated pig} cell nucleus is a fibroblast cell or cell nucleus.

c 10. The method according to claim 1, wherein the differentiated pig cell or ^{differentiated pig} cell nucleus is an adult cell or ^{adult} cell nucleus.

Sub
AI [11. The method according to claim 1, wherein the differentiated pig cell or cell nucleus is an embryonic or fetal cell or cell nucleus.

12. The method according to claim 1, wherein the enucleated oocyte is matured prior to enucleation.

55

c

2

~~used~~ nuclear transfer unit is activated by exposure to a single electrical pulse.

c

~~fused~~ nuclear transfer unit is activated by exposure to at least one activating factor ^{isolated} ~~derived~~ from sperm cells.

microinjection is used to insert a heterologous DNA.

electroporation is used to insert a heterologous DNA.

Sul
A2

19. An offspring obtained according to the method of claim 2.

56

22. A transgenic offspring obtained according to the method of claim 4.

24. The method according to claim 1, which further comprises combining the cloned NT unit with a fertilized embryo to produce a chimeric embryo.

26. A fetus obtained according to the method of claim 24.

27. An offspring obtained according to the method of claim 25.

5x

29. A method of producing a CICM cell line, comprising:

(i) inserting a desired differentiated pig cell or cell nucleus into an enucleated pig oocyte, under conditions suitable for the formation of a nuclear transfer (NT) unit;

(ii) activating the resultant nuclear transfer unit; and

(iii) culturing cells obtained from said cultured NT unit to obtain a pig CICM cell line.

30. The method of claim 29, which comprises culturing said activated nuclear transfer unit until greater than the 2-cell developmental stage..

31. A CICM cell line obtained according to the method of claim 29.

32. The method according to claim 29, wherein a desired DNA is inserted, removed or modified in said differentiated pig cell or cell nucleus, thereby resulting in the production of a genetically altered NT unit.

33. A transgenic CICM cell line obtained according to claim 32.

20070707 150800

Sub
A5

~~of claim~~
~~duced to~~

~~ifferen~~

36. A method of therapy which comprises administering to a human patient in need of cell transplantation therapy xenogenic differentiated cells according to claim 35.

37. The method of Claim 36, wherein said cell transplantation therapy is effected to treat a disease condition selected from the group consisting of Parkinson's disease, Huntington's disease, Alzheimer's disease, spinal cord defects or injuries, multiple sclerosis, muscular dystrophy, cystic fibrosis, liver disease, heart disease, cartilage defects or injuries, burn ulcers, vascular disease, urinary tract disease and cancer.

38. A method of therapy which comprises administering to a human patient in need of cell transplantation therapy xenogenic cells obtained from a human according to claim 18.

from the group consisting of Huntington's disease, Affects or injuries, cystic fibrosis, I cartilage defects ar disease, urinary

38. A method of therapy which comprises administering to a human patient in need of cell transplantation therapy xenogenic cells obtained from a fetus according to claim 18.

0688057-0709

40. A method of therapy which comprises administering to a human patient in need of cell transplantation therapy xenogenic cells obtained from an offspring according to claim 19.

41. The method of Claim 40, wherein said cell transplantation therapy is effected to treat a disease or condition selected from the group consisting of Parkinson's disease, Huntington's disease, Alzheimer's disease, ALS, spinal cord defects or injuries, multiple sclerosis, muscular dystrophy, cystic fibrosis, liver disease, diabetes, heart disease, cartilage defects or injuries, burns, foot ulcers, vascular disease, urinary tract disease, AIDS and cancer.

43. The method of Claim 42, wherein said cell transplantation therapy is effected to treat a disease or condition selected from the group consisting of Parkinson's disease, Huntington's disease, Alzheimer's disease, ALS, spinal cord defects or injuries, multiple sclerosis, muscular dystrophy, cystic fibrosis, liver disease, diabetes, heart disease, cartilage defects or injuries, burns, foot ulcers, vascular disease, urinary tract disease, AIDS and cancer.

45. The method of Claim 44, wherein said cell transplantation therapy is effected to treat a disease or condition selected from the group consisting of Parkinson's disease, Huntington's disease, Alzheimer's disease, ALS, spinal cord defects or injuries, multiple sclerosis,

muscular dystrophy, cystic fibrosis, liver disease, diabetes, heart disease, cartilage defects or injuries, burns, foot ulcers, vascular disease, urinary tract disease, AIDS and cancer.

46. A method of producing a pharmaceutically active protein, comprising isolating a pharmaceutically active protein which is expressed by a transgenic offspring according to claim 22.

47. The method according to claim 29, which further comprises combining the cloned NT unit with a fertilized embryo to produce a chimera.

48. The method according to claim 47, which further comprises developing the chimeric CICM cell line to a chimeric embryo.

49. A chimeric embryo obtained according to claim 48.

50. The method according to claim 48, which further comprises developing the chimeric embryo to a chimeric fetus.

51. A chimeric fetus obtained according to claim 50.

0388057.070397

Sub
a7

52. The method according to claim 50, which further comprises developing the chimeric fetus to a chimeric offspring.

53. A chimeric offspring obtained according to claim 52.

54. The method according to claim 47, wherein a desired DNA is inserted, removed or modified in said differentiated pig cell or cell nucleus, thereby resulting in the production of a genetically altered NT unit.

55. The method according to claim 54, which further comprises developing the chimeric C1CM cell line to a chimeric embryo.

56. A chimeric embryo obtained according to claim 55.

57. The method according to claim 55, which further comprises developing the chimeric embryo to a chimeric fetus.

58. A chimeric fetus obtained according to claim 57.

0888057.070397
258070 2588880

ag

Sub
af

sub
C4

59. 60. A chimeric offspring obtained according to claim

61. A method of cloning a pig, comprising:

- (i) inserting a desired differentiated pig CICM cell or cell nucleus into an enucleated pig oocyte, under conditions suitable for the formation of a nuclear transfer (NT) unit;
- (ii) activating the resultant nuclear transfer unit;

and

- (iii) transferring said cultured NT unit to a host mammal such that the NT unit develops into a fetus.

62. The method according to claim 61, which comprises culturing said activated nuclear transfer unit until greater than the 2-cell developmental stage.

~~63.~~ The method according to claim ~~61~~, which further comprises developing the fetus to an offspring.

64. A fetus obtained according to the method of claim 61.

58

74. An offspring according to claim 60, which comprises an agriculturally useful trait.

75. An offspring according to claim 65, which comprises an agriculturally useful trait.

76. A transgenic pig.

77. An organ for use as an organ xenograft, which is obtained from the offspring according to claim 76.

78. The method according to claim 45, wherein the pharmaceutically active protein is isolated from milk of the transgenic offspring.

Sub
a8

Sub
a9

Add
a10